Ultimovacs Feed

Land	Norge
Lista	OB Match
Sektor	Hälsovård
Industri	Bioteknik

2022-05-12 08:00:00 Ultimovacs ASA: First quarter 2022 result presentation +3,36% | 3,30 MNOK

2022-05-10 08:00:00 Ultimovacs Announces Presentation of UV1 Immune Monitoring Data at Cancer Immunotherapy Annual Meeting +1,83% | 3,71 MNOK

2022-05-05 08:00:00 Ultimovacs ASA: Invitation to first quarter 2022 results webcast presentation +2,32% | 1,38 MNOK

2022-04-22 08:00:00 Ultimovacs Receives Notice of Allowance on US Patent on Vaccine-Checkpoint Inhibitor Combinations +2,33% | 9,93 MNOK

2022-04-21 16:30:00 Ultimovacs ASA - Share Option Program +2,33% | 9,93 MNOK

2022-04-21 11:14:33 Ultimovacs ASA – Annual General Meeting held on 21 April 2022 0,00% | 2,30 MNOK

2022-04-08 19:00:00 Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development -1,86% | 2,90 MNOK

2022-04-08 16:30:00 Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting -1,86% | 2,90 MNOK

2022-03-30 11:00:00 Ultimovacs to host Investor Days 2022: Meet the Team +0,98% | 2,00 MNOK

2022-03-25 08:47:06 Correction: Ultimovacs ASA: Annual Report 2021 +4,00% | 3,76 MNOK

2022-03-25 07:50:00 Ultimovacs ASA: Notice of Annual General Meeting on 21 April 2022 +4,00% | 3,76 MNOK

2022-03-25 07:30:00 Ultimovacs ASA: Annual Report 2021 +4,00% | 3,76 MNOK

2022-03-21 08:00:00 Ultimovacs Hosting Key Opinion Leader Webinar on the Evolving Treatment Landscape of Melanoma +0,39% | 3,08 MNOK

2022-03-09 16:30:00 Ultimovacs to Present Preclinical Data on TET Platform at American Association for Cancer Research (AACR) 2022 Annual Meeting -5,63% | 4,28 MNOK

2022-03-09 16:30:00 ULTI: Ultimovacs to Present Preclinical Data on TET Platform at American Association for Cancer Research (AACR) 2022 Annual Meeting -5,63% | 4,28 MNOK

2022-02-17 13:18:22 Ultimovacs ASA: Mandatory notification of trade by primary insider -6,17% | 9,45 MNOK

2022-02-17 13:18:17 Ultimovacs ASA: Mandatory notification of trade by primary insider -6,17% | 9,45 MNOK

2022-02-17 08:00:00 Ultimovacs ASA: Fourth quarter 2021 result presentation -6,17% | 9,45 MNOK

2022-02-10 08:00:00 Ultimovacs ASA: Invitation to fourth quarter 2021 results webcast presentation -1,70% | 1,83 MNOK

2022-02-03 08:00:00 Ultimovacs to Progress to Last Cohort in Phase I Prostate Cancer TENDU study +1,96% | 3,84 MNOK

2021-12-20 09:20:01 ULTI: Financial calendar +0,96% | 5,91 MNOK

2021-12-15 08:00:00 First Patient Enrolled in Phase II DOVACC trial of UV1 in Advanced Ovarian Cancer -7,59% | 15,6 MNOK

2021-12-02 19:00:00 Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma +0,37% | 16,8 MNOK

2021-12-02 16:30:00 Ultimovacs ASA: Mandatory notification of trade by primary insider +0,37% | 16,8 MNOK

2021-11-29 20:15:20 Ultimovacs ASA: Mandatory notification of trade by primary insider +0,35% | 4,53 MNOK

2021-11-29 20:15:15 Ultimovacs ASA: Mandatory notification of trade by primary insider +0,35% | 4,53 MNOK

2021-11-25 08:00:00 Ultimovacs ASA: Mandatory notification for close associate +3,02% | 5,05 MNOK

2021-11-11 08:00:00 Ultimovacs ASA: Third quarter 2021 result presentation -0,47% | 12,5 MNOK

2021-11-09 14:00:00 Ultimovacs’ SITC2021 Data Shows Enduring T cell Response for UV1 Combination in Melanoma -0,60% | 15,3 MNOK

2021-11-03 08:00:00 Ultimovacs ASA: Invitation to third quarter 2021 results presentation -0,63% | 10,8 MNOK

2021-11-02 10:57:35 Ultimovacs ASA – New share capital registered +0,31% | 8,74 MNOK

2021-10-27 07:37:31 Ultimovacs ASA – Transactions by primary insiders and closely associated parties -4,03% | 305 MNOK

2021-10-27 00:23:44 Ultimovacs ASA - Private placement of new shares successfully placed +2,97% | 10,9 MNOK

2021-10-27 00:06:50 Ultimovacs ASA - Private placement of new shares successfully placed +2,97% | 10,9 MNOK

2021-10-26 16:47:38 Ultimovacs to Launch Phase II Combination Trial of UV1 in Lung Cancer (NSCLC) -4,03% | 305 MNOK

2021-10-26 16:31:00 Ultimovacs ASA - Contemplated private placement -4,03% | 305 MNOK

2021-10-26 16:30:00 Ultimovacs to Launch Phase II Combination Trial of UV1 in Lung Cancer (NSCLC) -4,03% | 305 MNOK

2021-10-21 08:05:00 Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma +12,58% | 41,7 MNOK

2021-10-21 08:00:00 Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma +12,58% | 41,7 MNOK

2021-10-15 10:51:04 Ultimovacs ASA: New share capital registered -5,82% | 30,3 MNOK

2021-10-13 08:33:58 Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer Vaccine-Pembrolizumab Combination Study in Metastatic Melanoma +14,08% | 44,5 MNOK

2021-10-13 08:00:00 Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer Vaccine-Pembrolizumab Combination Study in Metastatic Melanoma +14,08% | 44,5 MNOK

2021-10-12 18:34:14 Ultimovacs ASA: Share capital increase related to exercise of options +14,08% | 44,5 MNOK

2021-10-08 09:07:18 Ultimovacs ASA announces Two Key Appointments to the Management Team as the Operations Advances +1,34% | 14,4 MNOK

2021-10-08 09:07:13 ULTI: Ultimovacs ASA announces Two Key Appointments to the Management Team as the Operations Advances +1,34% | 14,4 MNOK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

2023-02-16	Bokslutskommuniké 2022
2022-11-10	Kvartalsrapport 2022-Q3
2022-08-19	Kvartalsrapport 2022-Q2
2022-05-12	Kvartalsrapport 2022-Q1
2022-04-21	Ordinarie utdelning ULTI 0.00 NOK
2022-04-20	Årsstämma 2022
2022-02-17	Bokslutskommuniké 2021
2021-11-11	Kvartalsrapport 2021-Q3
2021-08-20	Kvartalsrapport 2021-Q2
2021-05-11	Kvartalsrapport 2021-Q1
2021-04-22	Ordinarie utdelning ULTI 0.00 NOK
2021-04-21	Årsstämma 2021
2021-02-17	Bokslutskommuniké 2020
2020-11-12	Kvartalsrapport 2020-Q3
2020-11-11	Extra Bolagsstämma 2020
2020-08-21	Kvartalsrapport 2020-Q2
2020-05-14	Kvartalsrapport 2020-Q1
2020-04-16	Ordinarie utdelning ULTI 0.00 NOK
2020-04-15	Årsstämma 2020
2020-02-14	Bokslutskommuniké 2019
2019-11-14	Kvartalsrapport 2019-Q3
2019-08-21	Kvartalsrapport 2019-Q2

Ultimovacs

Beskrivning

Kalender

Ultimovacs

Beskrivning

Kalender

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden